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BACKGROUND & AIMS:
Several models have been used to determine prognoses of patients with alcoholic hepatitis. These include static systems (the Maddrey discriminant function; age, bilirubin, international normalized ratio, creatinine [ABIC] score; and model for end-stage liver disease [MELD] score) and dynamic models (the Lille model). We aimed to combine features of all of these models to develop a better method to predict outcomes of patients with alcoholic hepatitis. METHODS: We collected data from several databases of patients with severe alcoholic hepatitis treated with corticosteroids in France and the United Kingdom to create a model to predict patient survival (derivation cohort, n ¼ 538 patients). We compared the performances of 3 joint-effect models (MaddreyþLille, MELDþLille, and ABICþLille) to determine which combination had the best prognostic value, based on known patient outcomes. The model was validated using data from trials of the effects of corticosteroids in patients in the United States, France, Korea, and Belgium (n ¼ 604 patients). RESULTS: We created a joint-effect model to predict patient survival after 2 and 6 months; in the derivation and validation cohorts it predicted outcome significantly better than either static or dynamic models alone (P < .01 for all comparisons). The joint model accurately predicted patient survival regardless of patient risk level. The MELDþLille combination was better than the MaddreyþLille or ABICþLille combination in predicting patient survival, with Akaike information criterion values of 1305, 1313, and 1312, respectively. For example, based on the MELDþLille combination model, the propose new therapies early on to patients with a high risk of short-term mortality. 1 For this reason, prognostic models at baseline (static models) and models after treatment (dynamic models) now are considered mandatory tools to determine patient outcome. Nevertheless, progress in the understanding of early prediction of mortality is still an important issue.
Pretreatment scores to measure the severity of alcoholic hepatitis such as the Maddrey discriminant function (DF); the Model for End-stage Liver Disease (MELD); age, bilirubin, international normalized ratio (INR), creatinine (ABIC); and Glasgow alcoholic hepatitis scores accurately predict shortterm mortality. [2] [3] [4] [5] [6] Although the decision to treat usually is based on a Maddrey DF greater than 32, the MELD score also is accurate and also could be used for this purpose 3, 6 even though the optimal cut-off value for the decision to treat must be proposed by experts. With prednisolone therapy, early improvement in liver function is associated strongly with a decrease in short-term mortality. This early improvement can be assessed by recalculating static prognostic models after a short evaluation period, or by using the Lille model, which includes a measurement of response to treatment. 7 For example, a 2 or more point change in the MELD score, as well as the Glasgow AH score, or the difference in bilirubin after 7 days of treatment, are predictive of in-hospital mortality. 4, 6, 8 The Lille model is more accurate in this setting than repeated calculation of prognostic scores 7 and permits identification of patterns of complete, partial, and null response, each associated with a risk of early death. 9 At present, to adapt the treatment strategy in patients with severe AH, prognosis is determined by the use of either static or dynamic models. A new notion is to combine the information from static and dynamic models to predict the risk of death on a continuum. This approach might make it possible to stratify the risk of death and provide a more precise estimation of outcome based on severity when management begins and after a short period of treatment. This approach would provide a more balanced evaluation rather than a yes/no prediction of death.
To develop a predictive model of mortality that integrates both static and dynamic models, a large sample of wellcharacterized patients is needed as well as laboratory and clinical data at baseline, response to treatment, and appropriate statistical analysis. The relationship between each model and mortality as well as the added value provided by their combinations must be tested. If this added value is confirmed, the combined approach can be considered better.
The aim of the present study was to improve the prediction of mortality using data from well-characterized cohorts in a large database by providing a risk prediction chart for mortality based on the combination of static and dynamic models.
Patients and Methods

Study Population and Assessment of Diagnosis
The patients included in this study were found in several prospective international databases grouped into derivation and validation cohorts. The derivation cohort included the following: (1) the local Lille database of patients who were followed up prospectively after the publication of the Lille model formula; (2) patients in a randomized controlled British trial testing antioxidants vs corticosteroids 10 ; (3) the local prospective database of the Medical Center of Angers, France; and (4) patients in the last randomized controlled French trial Corpentox. 11 Duplicates were discarded from this latter cohort (Corpentox) because some patients also were included in the local Lille and Angers databases. The validation cohort included the following: (1) patients in an American trial testing oxandrolone and prednisolone 12 ; (2) the Lille model prospective cohort (patients included in the development and validation of the Lille model 7 from Paris, Béthune, and Lille, France); (3) patients in a Korean trial testing pentoxifylline vs prednisolone 13 ; (4) a local database from Bondy, France; and (5) a local database from Brussels, Belgium. Data from another trial were available 14 but we decided to exclude them because 6-month survival date were not available for this cohort (the primary end point was 28-day survival). Study flow charts are presented in Supplementary Figures 1 and 2 .
The diagnosis of AH was based on the following criteria in all cohorts: (1) recent onset of jaundice (<3 mo); (2) a history of long-standing alcoholism; (3) biological profile of alcoholic hepatitis with moderately increased transaminase and increased bilirubin levels 15 ; (4) absence of recent severe gastrointestinal hemorrhage (ie, <15 days); and (5) absence of active peptic ulcers, neoplasms, and nonalcoholic liver disease (in particular, negative serologic markers for hepatitis B and C virus and for human immunodeficiency virus infection). It should be noted that information on the recent onset of jaundice and the exclusion of patients with gastrointestinal bleeding was not available in 2 trials 10,12 and 1 trial, 12 respectively. All French and Belgian subjects underwent a transjugular liver biopsy in accordance with standard clinical practice in France and Belgium. 1, 16 A liver biopsy was performed in 68% of the cases in the Phillips et al 10 study. No histologic confirmation was required in the randomized controlled trial published by Mendenhall et al 12 and by Park et al. 13 Only patients with severe AH at admission were included in the combined database, as defined by a Maddrey DF of 32 or higher. The Maddrey DF was calculated with the following formula: 4.6*(patient prothrombin time -control prothrombin time) þ total bilirubin in mg/dL. 5 A few patients (3%) admitted with a Maddrey DF of 32 or higher improved before corticosteroids were begun and had a Maddrey DF of less than 32 when treatment was begun. We decided to keep these patients in the analysis because they had severe AH at inclusion. The ABIC and MELD scores were calculated with the formulas provided in the descriptions of their utility in severe AH 2, 3, 6 (Supplementary Table 1 ).
Treatment
All patients included in the present study were treated with corticosteroids. Patients in the different studies who did not receive corticosteroids were excluded (eg, if they were randomized to a placebo arm). All patients in the Corpentox study were included in the current analysis because no difference in survival was observed in the group treated with prednisolone and pentoxifylline compared with prednisolone alone. The treatment protocol with corticosteroids was slightly different depending on the study (40 mg/day in the French, Belgian, and Korean studies; 30 mg/day in the Phillips et al 10 study; 60 mg/ day for 4 days then tapered down to 5 mg/day for a total of 30 days in the Mendenhall et al 12 study). The response to treatment was assessed by the Lille model, which was calculated after 7 days of corticosteroid treatment using the following formula: exp (-R)/(1 þ exp[-R]) in which R ¼ 3.19 -0.101 * age (years) þ 0.147 * albumin (g/L) þ 0.0165 * change in bilirubin (mmol/L) -0.206 * (renal insufficiency) -0.0065 * bilirubin day 0 (mmol/l) -0.0096 * prothrombin time (seconds). 7 The Lille score ranges from 0 to 1, with higher scores associated with higher mortality. Change in bilirubin level is defined as the difference between total bilirubin at day 0 and total bilirubin at day 7. Renal insufficiency is rated as 0 if creatinine level is less than 1.3 mg/dL at day 0 and as 1 if it is greater than 1.3 mg/dL. We used the last available albumin value before infusion in patients treated with albumin infusion. The formula of the Lille model is available online at http://www.lillemodel.com. Further information on the calculation and interpretation of all prognostic scores can be found in Supplementary Table 1 .
Clinical and Biological Data
The following variables were assessed at baseline: age, sex, serum bilirubin level, prothrombin time, INR, serum albumin level, serum creatinine level, Maddrey DF, ABIC score, and MELD score. The Lille model was calculated after 7 days. The follow-up period was defined as the period from admission to 6 months after the initiation of corticosteroids. Data from patients lacking the events of interest were censored at the date of the last follow-up visit.
Statistical Analysis
Quantitative variables are expressed as means (standard error) if the distribution was normal or medians (interquartile range) otherwise. Categoric variables are expressed as frequencies and percentages.
The primary aim of this study was to provide a risk prediction chart for overall mortality based on baseline Maddrey DF and the Lille model in a derivation data set. Survival curves were estimated using the Kaplan-Meier method. Overall mortality predicted by the Maddrey DF and Lille score was calculated with the Cox proportional hazards model stratified for the cohort. The log-linearity assumption of both scores was assessed, first, using Martingale residual plots, and, second, using restricted cubic spline functions. 17 We used the 3-knot cubic spline and knots were determined using the Daspline SAS macro. 18 The spline was introduced into the model if the likelihood ratio tested for comparison with the model including only a linear term was significant. Interaction between the Maddrey DF and the Lille model was tested by introducing a multiplicative term into the Cox regression model. Because we found no evidence of an interaction (P ¼ .59), the joint-effect model was fitted without an interaction term.
The proportional hazard assumption was assessed by plotting the Schoenfeld residuals for the prognostic index calculated from the joint-effect model against the rank of survival time. 19 We also examined the performance of the jointeffect model by determining its calibration and discrimination. Discrimination was evaluated using the Harrell's c-index of agreement, 17 which indicates to what extent the model distinguishes patients who will die from those who will survive. This c-statistic has a typical range of 0.6 to 0.85 for survival data. 20 Calibration is the agreement between the predicted and observed mortality, and was evaluated by comparing the predicted mean survival curves with the Kaplan-Meier survival curves in the 4 risk groups. 21 To obtain a reasonable risk spread, the 4 risk groups were determined using the 16th, 50th, and 84th centiles of the prognostic index. 21 We reported the predicted and observed probabilities of overall mortality at 2 specific time points (at 2 and 6 months). We derived the predicted mortality probabilities by pooling the baseline survival estimates from cohorts at the mean values of predictors in the derivation data set.
We performed internal validation by using bootstrap resampling with 200 repetitions to estimate shrinkage factors and the c-statistic corrected for overoptimism. Risk prediction charts were built from the estimated multivariable model (after shrinking the regression coefficients to improve the prediction in future patients, 17 see the Appendix for the scoring system). This chart was represented using a contour plot showing the joint effect of the Maddrey DF and the Lille model on the overall mortality probabilities.
We performed an external validation of the scoring system by assessing model calibration and discrimination performances in the validation data set. Mortality probabilities were calculated using the coefficient estimates (after applying the shrinkage factor) and the pooled baseline survival estimate from the derivation data set (see the Appendix for the scoring system).
A secondary aim of this study was to provide similar risk prediction charts using other widely used static models, namely the MELD and ABIC scores. We used the same approach as with the primary aim. Because of missing data on individual score components, the MELD and ABIC scores were available for a subset of patients included in the primary analysis. We therefore performed a sensitivity analysis for the prediction of the probabilities of mortality with the Maddrey DF and Lille model and we used Akaike Information Criterion (AIC) to determine the best-fitted model of the 3 joint-effect models. 22 We used the AIC rather than the C-statistic because the latter is not sensitive for capturing overall added values from a new "marker" on top of conventional predictors. 23 Statistical testing was performed at the 2-tailed a level of .05. Data were analyzed using the SAS software package, release 9.3 (SAS Institute, Cary, NC).
Results
The derivation data set was drawn from 4 pooled cohort studies including a total of 605 patients and the validation data set was drawn from 8 pooled cohort studies including a total of 712 patients. Sixty-seven patients from the derivation data set (11%) and 108 patients from the validation data set (15%) were excluded from primary analysis of the joint effect of the Maddrey DF and the Lille model on overall survival because they died within 7 days (n ¼ 22 and n ¼ 25, respectively) or had missing information (n ¼ 45 and n ¼ 83, respectively) ( Supplementary Figures 1 and 2 ). Because the INR was not available for 3 cohorts, the MELD score was not assessed systematically in all cohorts. Thus, the derivation analysis of the joint effect of the MELD score and the Lille model (secondary analysis) was performed in 473 patients and the validation analysis was performed in 410 patients ( Supplementary Figures 1 and 2) . Table 1 shows the baseline characteristics (ie, characteristics at the beginning of corticosteroid treatment) of both the derivation (n ¼ 538) and validation (n ¼ 604) data sets for primary analysis; the baseline characteristics of each cohort for primary analysis and of pooled cohorts for secondary analysis are provided in Supplementary Tables 2-4 . After a follow-up period of 6 months, 175 deaths occurred in the derivation cohort and 221 occurred in the validation cohort. Overall survival at 2 and 6 months was within the range of previously published studies for both cohorts, with Kaplan-Meier estimates of 76.1% (95% confidence interval [CI], 72.2-79.5) and 66.8% (95% CI, 62.6-70.6) in the derivation cohort, and 73% (95% CI, 69.2-76.5) and 61.6% (95% CI, 57.4-65.4) in the validation cohort, respectively.
Considering that the Lille score integrates the change in bilirubin level between day 0 and day 7, we evaluated whether a change in baseline scores could predict patient outcome. A change in baseline score did not improve the prediction of outcome as compared with the score at baseline (Supplementary Results).
Lille Model and Maddrey DF
The Lille model and the Maddrey DF were associated with an increased risk in overall mortality (P < .001) in univariate analysis, assessed by a linear relationship between the log relative risk of death and each of the 2 scores (Lille model and Maddrey DF) (Supplementary Figure 3) ; the Cox regression model fit was not improved using the cubic spline function for each score (P > .29 for both scores). The likelihood of the multivariable Cox regression model including the Lille model and Maddrey DF (jointeffect model) was improved significantly compared with the model based on the Lille model alone (c 2 ddl¼1 ¼ 11, P ¼ .001) or the Maddrey DF (c 2 ddl¼1 ¼ 102, P < .001); thus, the Lille model and Maddrey DF were independent predictors of overall mortality. NOTE. The risk group was defined by the 16th, 50th, and 84th centiles of the prognostic index derived by the Cox's regression model from the derivation data set. N and event denote the number of patients and death in each risk group. The observed and predicted probabilities of overall mortality at 2 and 6 months are shown; values labeled observed were calculated using Kaplan-Meier estimates and values labeled predicted were calculated as the mean predicted probabilities by the Cox regression model derived in the derivation data set across each risk group (predicted estimates in the validation data set use shrinkage factor, estimated using bootstrap validation in the derivation data set, see Appendix 1). There was good discrimination of this joint-effect model in the derivation (c-statistic corrected for overoptimism, 0.75; 95% CI, 0.72-0.79) and validation cohorts (c-statistic, 0.78; 95% CI, 0.75-0.81) with, however, a breach of the proportional hazard assumptions (in both the derivation and validation data sets). This means that the joint-effect model accurately distinguishes patients who will die from those who will survive. As shown in Table 2 , calibration was good in the 4 risk-of-mortality groups, meaning that the predicted and observed mortalities were close in each group. A slight overprediction in the derivation cohort and an underprediction in the validation cohort were observed in the group with a very high risk of mortality. Figure 1A and B show how the joint-effect model converts any individual score (Maddrey DF or Lille model) into a continuum risk of mortality at 2 and 6 months according to the value of the other score in the derivation cohort. Contour lines link the points of equal probability of death to help the clinician interpret the model. For example, when the Maddrey DF was between 30 and 180, the predicted 6-month mortality ranged from 12.6% to 39.9% in a complete responder (Lille score, 0.16), and from 24.4% to 65.3% in a nonresponder (Lille score, 0.45). The jointeffect model predicts a 1.9-fold increased risk of mortality between 2 patients with the same Maddrey DF at 56 (median value of the last randomized controlled trial published by our group 11 ), one classified as a complete responder with a Lille score of 0.16 and the other classified as a nonresponder with a Lille score of 0.45 (15.6% vs 29.7%). To improve the readability of Figure 1 , the example of the patient with Maddrey DF at 56 at baseline with a Lille model at day 7 at 0.45 was plotted in Figure 1B .
Lille Model and MELD Score
We created another joint-effect model for secondary analysis that integrated baseline information from the MELD score, which has been shown to predict outcome effectively in AH. The MELD score was associated with an increased risk of overall mortality (P < .001) in univariate analysis. There was a linear relationship between the log relative risk of death and the MELD score (Supplementary Figure 3) and the Cox regression model fit was not improved by cubic spline function (P ¼ .26 for the comparison between the model including the linear term and the model including cubic spline function).
The likelihood of the multivariable Cox regression model including the Lille score and the MELD score was improved Figure 1 . Two-and 6-month overall mortality probability according to the joint-effect model combining the Lille model and Maddrey DF. þ, hypothetical patient with a Maddrey DF at 56 at baseline and a Lille score at 0.45: 2-month mortality rate is 19.8% and 6-month mortality rate is 29.6%.
significantly compared with the models with the Lille score (c 2 ddl¼1 ¼ 17; P < .001) or the MELD score (c 2 ddl¼1 ¼76; P < .001) alone, meaning that both the Lille and MELD scores were independent predictors of mortality. Discrimination of the joint-effect model was good in the derivation (c-statistic corrected for overoptimism, 0.76; 95% CI, 0.72-0.80) and validation data sets (c-statistic, 0.77; 95% CI, 0.74-0.81) with, however, a breach of the proportional hazard assumptions (in both the derivation and validation cohorts). Again, this means that the jointeffect model accurately distinguishes patients who will die from those who will survive. Calibration was good in the 4 mortality risk groups, meaning that predicted and observed mortalities were close (Table 3) . We observed a slight overprediction in the derivation cohort and underprediction in the validation cohort in the very high mortality risk group. Figure 2 shows the estimates of mortality (see the scoring system combining prognostic scores in Appendix 2) according to the Lille and MELD scores (overall mortality at 2 months [ Figure 2A ], and overall mortality at 6 months [ Figure 2B] ). When the MELD score was between 15 and 145, the predicted 6-month mortality was between 8.5% and 49.7% in a complete responder (Lille score, 0.16), and from 16.4% to 75.2% in a nonresponder (Lille score, 0.45). Conversely, when the Lille score was between 0 and 1, the predicted 6-month mortality was between 8.6% and 64.4% (MELD score, 21). 3 The joint-effect model predicts a 1.9-fold increased risk of mortality between 2 patients with a MELD score of 21, which is a proposed cut-off value for severity, 3 1 classified as a complete responder with a Lille score of 0.16 and the other classified as a nonresponder with a Lille score of 0.45 (12.5% vs 23.7%). The example of the patient with a MELD score at 21 at baseline with a Lille model at day 7 at 0.45 was plotted in Figure 2B .
Lille Model and ABIC Score
We found that the relationship between the ABIC score, a static model specifically designed for alcoholic hepatitis, and the log relative risk of death also was linear (Supplementary Figure 1) , and that a model combining the ABIC and Lille scores was improved compared with models including the ABIC (c 2 ddl¼1 ¼ 53; P < .001) or Lille (c 2 ddl¼1 ¼ 10; P ¼ .002) scores alone. Supplementary  Figure 4 shows the probability of death at 2 and 6 months. As for the other joint-effect models, the calibration of the combined ABIC þ Lille model was good in the derivation and validation cohorts (Supplementary Table 5 ).
Detection of Differences in Prediction by Joint-Effect Models
We used the AIC criteria (a measure derived from the likelihood model) to compare the performances of the 3 joint-effect models (MaddreyþLille, MELDþLille, and ABICþLille). The lower the AIC, the better the joint-effect model fits expected mortality. A comparison of the AIC of the 3 joint-effect models combined with the Lille model in the derivation cohort without missing baseline scores showed that the model including the MELD score (MELDþLille) had a lower AIC value (AIC, 1305) than that including the Maddrey DF (MaddreyþLille AIC, 1313) or the ABIC score (ABICþLille AIC, 1312), showing that the latter was the best-fitting prognostic model. Similar results were observed in the validation cohort (data not shown). NOTE. The risk group was defined by the 16th, 50th, and 84th centiles of the prognostic index derived by the Cox regression model from the derivation data set. N and event denote the number of patients and death in each risk group. The observed and predicted probabilities of overall mortality at 2 and 6 months are shown; values labeled observed were calculated using Kaplan-Meier estimates and values labeled predicted were calculated as the mean predicted probabilities by the Cox regression model derived in the derivation data set across each risk group (predicted estimates in validation data set use shrinkage factor, estimated using bootstrap validation in the derivation data set, see Appendix 2).
We have provided a web calculator at http://www. lillemodel.com to help the clinician evaluate the patient's risk of death using the 3 joint-effect models.
Discussion
The present study evaluates the benefit of using an approach that combines the prognostic information from static and dynamic models of severe AH. We provide a continuum of risk of death from 0% to 100% that fits observed mortality. Instead of a simple yes/no response, clinicians can target patients according to a more precise prediction of their outcome. This study shows that therapeutic management tailored to the magnitude of risk of mortality is possible; this could be used as a tool for the future evaluation of new molecules to determine a plan of development for phase 1 to phase 3 trials.
We confirm the prognostic value of static models such as the Maddrey DF, MELD score, and ABIC score, as well as the dynamic Lille model in predicting survival in patients with alcoholic hepatitis. All of these scores can be considered accurate because each of them is associated significantly with a risk of mortality. The benefit of combining a static model with the dynamic Lille model was confirmed by the significant improvement of the joint-effect model in predicting survival compared with each model alone.
The joint-effect models were developed in a derivation cohort and tested in a validation cohort. The predictive value of all joint-effect models is better than all models based on static (ie, Maddrey DF, ABIC, MELD scores) or dynamic scores (Lille model) alone and the calibration is good. Thus, all joint-effect models can be used to improve the prediction of mortality. Although we found a breach in the assumption of proportional hazards that could influence prediction, the agreement between observed and predicted mortality (ie, the calibration) is good and discrimination is preserved in both cohorts. The greatest difference between the predicted and observed probability of mortality was at 2 months in the highest-risk group; this difference (w10%) has a minor influence on patient management. Indeed, this slight difference does not affect clinical decisions because observed and predicted mortalities are both very high in this group (>60%). These results confirm that the combined approach using both static and dynamic models is robust.
According to AIC criteria calculated from the same sample, the MELDþLille joint-effect model was the bestfitting prognostic model (AIC, 1305 vs 1312 for ABICþLille and 1313 for Maddrey DFþLille). These data Figure 2 . Two-and 6-month overall mortality probability according to the joint-effect model combining the Lille model and MELD score. þ, hypothetical patient with a MELD score at 21 and a Lille score at 0.45: 2-month mortality rate is 15.3% and 6-month mortality rate is 23.7%. may help determine the best model combination. The integration of static and dynamic models provides a prediction continuum of the risk of mortality with information that is useful for adapting therapeutic strategies.
In relation to resistance to corticosteroids the joint-effect models identify a high risk of death in patients previously classified as responders and an intermediate risk of death in patients who previously were classified as nonresponders. Early liver transplantation for patients with severe AH who do not respond to medical treatment remains controversial. The use of liver transplantation for AH is criticized because patients with a disease that is not considered to have a clearly established indication are given priority on the waiting list. Besides the ethical issues, the time required for the selection process must be adapted to the risk of mortality. In particular, the use of a single cut-off value with the Lille model could result in the selection of certain patients for liver transplantation who are characterized as nonresponders to medical therapy, but who have a low risk of mortality without transplantation and who could be referred for further medical management of an alcohol-use disorder including ongoing abstinence from alcohol. For example, a patient admitted with a MELD score of 30 and a Lille score of 0.56 has a predicted risk of death of 33% and 48% at 2 and 6 months, respectively, whereas another patient with the same MELD score at baseline, also classified as a nonresponder with a Lille score of 0.85, has an estimated mortality of 56% and 73% at 2 and 6 months, respectively. In the first case, clinicians may have time to use a standard selection process whereas in the second case there is very little time to make a decision for early transplantation. The prediction of a continuum of risk of mortality can be very helpful in selecting patients for early liver transplantation. The combined approach also shows that corticosteroid treatment is not enough in some patients who still have a significant risk of death. Only expert panels can determine the limits and decide when patients are no longer benefitting from corticosteroids based on the risk of death.
At first glance, the present approach based on jointeffect models may seem to be restricted to studies in patients treated with corticosteroids. However, the efficacy of static and dynamic scores also has been shown in control groups that are not receiving corticosteroids, such as placebo or pentoxifylline. 3, 6, 7, 9, 13 Although the prognostic value of those scores is equivalent in corticosteroid-treated and control group patients, the magnitude of response and the probability of being classified as a responder are higher in patients treated with corticosteroids. 9 The combined approach could be used in future trials that do or do not test corticosteroids. For example, in phase II or III trials the tested molecule could be administered in a lead-in phase of 7 days, after which patients who are identified with a low risk of death could continue to receive the tested molecule. On the other hand, a switch or add-on therapeutic strategy with corticosteroids could be proposed for patients with a higher predicted risk of death than that in the planned study design. This new type of study design is based on the fact that static, dynamic, and joint-effect models are effective in patients with severe AH whatever the treatment because the outcome of these patients is driven by the severity of the disease at baseline and by early improvement after treatment. At present, molecules or therapeutic strategies for AH are being evaluated in only phase 3 studies. However, to evaluate new treatments, health agencies require a plan of development including phase 1 to phase 3 studies. Our results make it possible to build-up phase 1-2 studies with the primary goal of testing whether a new molecule can reduce liver injury without severe side effects, thus making it a candidate for further evaluation. The design of these phase 1-2 studies requires inclusion of patients with a very low competitive risk of mortality (ie, <10%) to have sufficient time of exposure to evaluate the pharmacologic effects.
In summary, we propose a new approach to predict outcome in patients with severe AH in terms of a continuum of mortality risk. This can help improve management of these patients as well as to develop clinical trials for future molecules and/or therapeutic strategies.
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Supplementary Results
Data on the evolution of the MELD score and Maddrey DF were available for 660 patients. In this group of patients, a change in baseline score had a lower discrimination index than the value at baseline and than the Lille model: a change in the MELD score Step 2: Calculate mortality probability using S: Step 2: Calculate mortality probability using S : Step 2: Calculate mortality probability using S : NOTE. The risk group was defined by the 16th, 50th, and 84th centiles of the prognostic index derived by the Cox regression model from the derivation data set. N and event denote the number of patients and death in each risk group. The observed and predicted probabilities of overall mortality at 2 and 6 months are shown; values labeled as observed were calculated using Kaplan-Meier estimates and values labeled as predicted were calculated as the mean predicted probabilities by the Cox regression model derived in the derivation data set across each risk group (predicted estimates in the validation data set use shrinkage factor, estimated using bootstrap validation in the derivation data set, see Appendix 3). 
Supplementary
